Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
- Before Adding AI, Fix The Process
- Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance
- How AI Will Reshape Study Start-Up
- Clinical Supply Systems Need IT General Controls
- Medical Affairs: The Missing Link To Oncology Drug Adoption
- Why ING Feels Different
- How Can We Influence Others For Better Outcomes In Clinical Research?
GUEST COLUMNISTS
-
![Teamwork, collaboration-GettyImages-2218614336]( "How Can We Influence Others For Better Outcomes In Clinical Research?")
How Can We Influence Others For Better Outcomes In Clinical Research?Learn how to use the Delphi method to build consensus and drive better decisions in clinical research — even when stakeholders start far apart.
-
![AI making money-GettyImages-2271467935]( "What Will Life Science Orgs Do When The AI Bill Comes Through?")
What Will Life Science Orgs Do When The AI Bill Comes Through?AI is transforming clinical development, but what happens when usage costs spike? Jon Newton explains how to govern it before the bill lands.
-
![Medical quality control-GettyImages-2072996733]( "Clinical Trial Standards — What They Are And Why They're Indispensable")
Clinical Trial Standards — What They Are And Why They're IndispensableClinical trial standards are essential. But to interpret changes, preserve meaning, and assess downstream impact, context is key.
-
![warehouse worker checking barcodes-GettyImages-2265704054]( "Last-Mile Lessons For Depot-To-Site Delivery")
Last-Mile Lessons For Depot-To-Site DeliveryDepot-to-site delivery is more than a courier handoff. See how reconciliation gaps, temperature risks, and mismatched SLAs can turn last-mile issues into trial delays.
-
![jackson AI part 2 using-GettyImages-2192428169]( "Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders")
Turn AI Visibility Into Action: Build Explanation Layers For Different StakeholdersAI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.
-
![Medical Hospital Surgery-GettyImages-2210492043]( "5 Ways To Enrich The Clinical Trial Ecosystem")
5 Ways To Enrich The Clinical Trial EcosystemSponsors must treat sites, PIs, and patients as connected parts of a living clinical trial ecosystem. Here are five ways to help make that happen.
-
![Risk Assessment-GettyImages-2192813165]( "The Promise Of MRD-Guided CAR-T Treatment")
The Promise Of MRD-Guided CAR-T TreatmentMinimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.
-
![online question and answer, problem-solving, and digital communication-GettyImages-2241803274]( "Your Trial Shows Up In AI. Now What?")
Your Trial Shows Up In AI. Now What?AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.
CLINICAL TRIAL WHITE PAPERS
-
![Faster Starts, Stronger Finish Operational Excellence In NSCLC]( "Faster Starts, Stronger Finish: Operational Excellence In NSCLC")
Faster Starts, Stronger Finish: Operational Excellence In NSCLCIn NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.
-
Decentralized And Community-Based Solutions Driving Women's Healthcare9/24/2025
Clinical trials should reflect the affected population by reducing participation barriers and bringing trials to patients to increase inclusion and improve real-world data.
-
Elevating Patient Centricity In Clinical Trials2/17/2025
How can the integration of patient perspectives throughout the clinical trial process enhance engagement and outcomes?
-
How Digitized Protocols Are Accelerating Clinical Research4/15/2025
Digitized protocols, enhanced by artificial intelligence (AI), are transforming clinical trial operations by accelerating document generation, system integration, and trial optimization.
-
Accelerate Drug Development With Master Protocols5/15/2025
Through careful planning, aligned incentives, and an open, adaptive mindset, master protocols become powerful engines for accelerating therapies to market—particularly in high-need therapeutic areas.
-
The Silent Saboteurs: Why Rater Drift And Site Unpreparedness Cost CNS Trials More3/25/2026
High-end technology cannot fix poor rater preparation or complex patient needs. True data integrity requires bridging the gap between digital platforms and the reality of clinical implementation.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Reframing Clinical Vendor Selection7/2/2025
Explore a platform that enables seamless vendor selection as well as cross-functional collaboration with built-in templates and tailored question libraries that simplify proposal creation and review.
-
Accelerating Approval Pathway For Phase III Ovarian Cancer Trial8/29/2025
A late-stage biotech developing a first-in-class therapy for a rare, chemo-resistant form of ovarian cancer sought help for accelerated FDA approval.
-
How A Leading Chinese Biopharmaceutical Company Modernized Clinical Operations7/15/2026
A growing biopharma pipeline needed better document oversight. Learn how automation and centralized tracking improved compliance and trial visibility.
-
Improving Clinical Trial Label Translation Through Centralized Reuse And Control8/10/2026
Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.
-
Duchenne Muscular Dystrophy Trial In China9/17/2025
A global sponsor conducting a Duchenne Muscular Dystrophy trial in China required reliable patient travel solutions to support children and families.
-
Driving ROI: A Real-Time Clinical Trial Oversight Solution8/3/2026
Sample errors, delays, and query overload drain clinical trial budgets. Learn how real-time data capture can shorten timelines and protect data quality.
NEWSLETTER ARCHIVE
- 09.18.26 -- The Promise Of MRD-Guided CAR-T Treatment
- 09.18.26 -- Patients Are Dropping Out — Here's How Sites Are Closing The Gap
- 09.17.26 -- Five Ways To Enrich The Clinical Trial Ecosystem
- 09.16.26 -- Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy
- 09.16.26 -- From Sample Handling To Site Support: What's Powering Trial Success
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
![jackson AI part 2 using-GettyImages-2192428169]( "Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders")
AI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.
-
![online question and answer, problem-solving, and digital communication-GettyImages-2241803274]( "Your Trial Shows Up In AI. Now What?")
AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.
-
![nurse and patient-GettyImages-1196843513]( "Sustainable Patient Engagement: Your Enrollment And Representation Depend On It")
Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.
FOCUS ON PATIENTS
-
![business man looking through telescope-GettyImages-2215651052]( "Why Oncology Programs Can't Rely On An Inside View Alone")
Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
-
![Risk Assessment-GettyImages-2192813165]( "The Promise Of MRD-Guided CAR-T Treatment")
Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.
-
![pharmacist, service, guidance, patient care-GettyImages-2260105068]( "The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option")
Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.
